(HUM) Humana - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4448591028

HUM: Insurance, Medical, Pharmacy, Dental, Vision, Life

Humana Inc. (NYSE: HUM) stands as a prominent player in the U.S. health insurance sector, operating through two primary segments: Insurance and CenterWell. The Insurance segment offers a diverse range of medical and specialty insurance products, including Medicare Advantage, Medicaid, and commercial group health insurance. CenterWell focuses on healthcare services, encompassing pharmacy benefit management, home health care, and senior-focused primary care centers. This dual structure allows Humana to integrate insurance with care delivery, fostering a value-based care approach that emphasizes preventive medicine and cost efficiency.

Humanas business model is bolstered by its robust administrative platform, which supports both fully insured and self-insured plans. The company has made significant investments in digital health technologies and data analytics to enhance member engagement and improve health outcomes. With a market capitalization of over $31 billion, Humanas financial profile includes a price-to-earnings ratio of approximately 25.79 and a forward P/E of 15.36, indicating expectations of future growth. The companys strategic focus on senior demographics and government-sponsored plans positions it well in a growing market, making it a notable consideration for investors seeking exposure to the managed healthcare sector.

Additional Sources for HUM Stock

HUM Stock Overview

Market Cap in USD 31,933m
Sector Healthcare
Industry Healthcare Plans
GiC Sub-Industry Managed Health Care
IPO / Inception 1993-01-22

HUM Stock Ratings

Growth 5y -28.0%
Fundamental 15.1%
Dividend 46.4%
Rel. Strength -22.3
Analysts 3.62/5
Fair Price Momentum 239.92 USD
Fair Price DCF 457.77 USD

HUM Dividends

Dividend Yield 12m 1.25%
Yield on Cost 5y 1.18%
Annual Growth 5y 7.20%
Payout Consistency 52.5%

HUM Growth Ratios

Growth Correlation 3m -20.9%
Growth Correlation 12m -70.4%
Growth Correlation 5y -15.3%
CAGR 5y -2.41%
CAGR/Max DD 5y -0.04
Sharpe Ratio 12m 0.59
Alpha -28.36
Beta 0.41
Volatility 30.21%
Current Volume 967.9k
Average Volume 20d 1324.2k
What is the price of HUM stocks?
As of March 29, 2025, the stock is trading at USD 264.58 with a total of 967,920 shares traded.
Over the past week, the price has changed by -0.27%, over one month by +1.53%, over three months by +4.77% and over the past year by -22.77%.
Is Humana a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Humana is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 15.14 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HUM as of March 2025 is 239.92. This means that HUM is currently overvalued and has a potential downside of -9.32%.
Is HUM a buy, sell or hold?
Humana has received a consensus analysts rating of 3.62. Therefor, it is recommend to hold HUM.
  • Strong Buy: 7
  • Buy: 2
  • Hold: 17
  • Sell: 0
  • Strong Sell: 0
What are the forecast for HUM stock price target?
According to ValueRays Forecast Model, HUM Humana will be worth about 259.1 in March 2026. The stock is currently trading at 264.58. This means that the stock has a potential downside of -2.07%.
Issuer Forecast Upside
Wallstreet Target Price 296.9 12.2%
Analysts Target Price 296.1 11.9%
ValueRay Target Price 259.1 -2.1%